WallStreetZenWallStreetZen

NASDAQ: TARS
Tarsus Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for TARS

Based on 1 analyst offering 12 month price targets for Tarsus Pharmaceuticals Inc.
Min Forecast
$40.00+146%
Avg Forecast
$40.00+146%
Max Forecast
$40.00+146%

Should I buy or sell TARS stock?

Based on 1 analyst offering ratings for Tarsus Pharmaceuticals Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TARS stock forecasts and price targets.

TARS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Barclays
Bottom 17%
17
Strong BuyInitiates Coverage On$40.00+146.00%2022-08-01

1 of 1

Forecast return on equity

Is TARS forecast to generate an efficient return?
Company
N/A
Industry
-0.01%
Market
13.24%

Forecast return on assets

Is TARS forecast to generate an efficient return on assets?
Company
N/A
Industry
0.12%

TARS earnings per share forecast

What is TARS's earnings per share in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
-$4.99
Avg 2 year Forecast
-$3.01
Avg 3 year Forecast
$0.15

TARS revenue forecast

What is TARS's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$6.0M-62.67%
Avg 2 year Forecast
$116.1M+618.62%
Avg 3 year Forecast
$241.2M+1,393.27%
TARS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TARS revenue growth forecast

How is TARS forecast to perform vs Biotechnology companies and vs the US market?
Company
146.25%
Industry
38.5%
Market
9.23%
TARS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TARS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TARS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TARS$16.26$40.00+146.00%Strong Buy
VECT$8.55$23.67+176.81%Strong Buy
VNDA$7.65$12.00+56.86%Hold
ESPR$5.90$12.33+109.03%Hold
NGM$5.40$12.00+122.22%Buy

Tarsus Pharmaceuticals Stock Forecast FAQ

Is Tarsus Pharmaceuticals Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: TARS) stock is to Strong Buy TARS stock.

Out of 1 analyst, 1 (100%) are recommending TARS as a Strong Buy, 0 (0%) are recommending TARS as a Buy, 0 (0%) are recommending TARS as a Hold, 0 (0%) are recommending TARS as a Sell, and 0 (0%) are recommending TARS as a Strong Sell.

If you're new to stock investing, here's how to buy Tarsus Pharmaceuticals stock.

What is TARS's earnings growth forecast for 2023-2025?

(NASDAQ: TARS) Tarsus Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 21.99%.

Tarsus Pharmaceuticals's earnings in 2023 is -$63,343,000.On average, 6 Wall Street analysts forecast TARS's earnings for 2023 to be -$133,094,218, with the lowest TARS earnings forecast at -$148,564,087, and the highest TARS earnings forecast at -$124,559,118. On average, 3 Wall Street analysts forecast TARS's earnings for 2024 to be -$80,283,286, with the lowest TARS earnings forecast at -$114,156,965, and the highest TARS earnings forecast at -$49,343,548.

In 2025, TARS is forecast to generate $4,000,828 in earnings, with the lowest earnings forecast at -$8,268,378 and the highest earnings forecast at $14,669,703.

What is TARS's revenue growth forecast for 2023-2025?

(NASDAQ: TARS) Tarsus Pharmaceuticals's forecast annual revenue growth rate of 146.25% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.5%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.23%.

Tarsus Pharmaceuticals's revenue in 2023 is $16,154,000.On average, 2 Wall Street analysts forecast TARS's revenue for 2023 to be $160,833,294, with the lowest TARS revenue forecast at $105,621,864, and the highest TARS revenue forecast at $216,044,723. On average, 3 Wall Street analysts forecast TARS's revenue for 2024 to be $3,096,267,616, with the lowest TARS revenue forecast at $2,195,921,238, and the highest TARS revenue forecast at $4,540,406,563.

In 2025, TARS is forecast to generate $6,433,945,206 in revenue, with the lowest revenue forecast at $5,457,129,665 and the highest revenue forecast at $7,646,116,134.

What is TARS's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: TARS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.12%.

What is TARS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year TARS price target, the average TARS price target is $40.00, with the highest TARS stock price forecast at $40.00 and the lowest TARS stock price forecast at $40.00.

The Wall Street analyst predicted that Tarsus Pharmaceuticals's share price could reach $40.00 by Aug 1, 2023. The average Tarsus Pharmaceuticals stock price prediction forecasts a potential upside of 146% from the current TARS share price of $16.26.

What is TARS's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: TARS) Tarsus Pharmaceuticals's current Earnings Per Share (EPS) is -$2.78. On average, analysts forecast that TARS's EPS will be -$4.99 for 2023, with the lowest EPS forecast at -$5.57, and the highest EPS forecast at -$4.67. On average, analysts forecast that TARS's EPS will be -$3.01 for 2024, with the lowest EPS forecast at -$4.28, and the highest EPS forecast at -$1.85. In 2025, TARS's EPS is forecast to hit $0.15 (min: -$0.31, max: $0.55).

What is TARS's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: TARS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.